Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 4/20 | 0.73 |
| ▸ | FABP3 | P05413 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.64 |
| ▸ | CSF1R | P07333 | 1/20 | 0.62 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL8121508 | 0.94 | FABP4 (0.66) | FABP4FABP3SMN1; SMN2LMNAMEN1 | |
| SCHEMBL14916920 | 0.91 | FABP4 (0.62) | FABP4FABP3SMN1; SMN2LMNAMEN1 | |
| Diethylamine SCHEMBL8131909 | 0.89 | FABP3 (0.58) | FABP4FABP3SMN1; SMN2LMNAMEN1 | |
| SCHEMBL3346637 | 0.88 | FABP4 (0.66) | FABP4FABP3SMN1; SMN2LMNAMEN1 | |
| SCHEMBL3321046 | 0.87 | FABP3 (0.56) | FABP4FABP3SMN1; SMN2LMNAMEN1 | |
| SCHEMBL3318169 | 0.87 | KDM4E (0.77) | FABP4FABP3SMN1; SMN2LMNAMEN1 | |
| SCHEMBL3319814 | 0.87 | FABP4 (0.65) | FABP4FABP3SMN1; SMN2LMNAMEN1 | |
| SCHEMBL31442597 | 0.87 | SMN1; SMN2 (0.81) | FABP4FABP3SMN1; SMN2LMNAMEN1 | |
| SCHEMBL14917264 | 0.86 | FABP4 (0.73) | FABP4FABP3SMN1; SMN2LMNAMEN1 | |
| SCHEMBL12498023 | 0.86 | SMN1; SMN2 (0.72) | FABP4FABP3SMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | LANDAUER, STEPHEN PAUL | 2024-10-03 | — | — | US | claimed |
| WO-2023009629-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-02-02 | — | — | WO | claimed |
| US-8865739-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-10-21 | — | — | US | claimed |
| US-20140107155-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-8664399-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | claimed |
| US-20130102632-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-25 | — | — | US | claimed |
| US-20100125091-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | US | claimed |
| WO-2010056865-A1 | QUINOLINE DERIVATIVES AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | LANDAUER, STEPHEN PAUL | 2024-10-03 | — | — | US | disclosed |
| WO-2023009629-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| US-8865739-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140107155-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8664399-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130102632-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20100125091-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056865-A1 | QUINOLINE DERIVATIVES AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107155-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | FABP4 3868/4885FABP3 1216/4885SMN1; SMN2 2201/4885 |
| US-20100125091-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | FABP4 3868/4885FABP3 1216/4885SMN1; SMN2 2201/4885 |
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | AKT3, AKT1, AKT2 | FABP4 1907/4885FABP3 969/4885SMN1; SMN2 1012/4885 |
| US-20130102632-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | FABP4 3868/4885FABP3 1216/4885SMN1; SMN2 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.